[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
3. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V: Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant; 2002 Feb;29(4):285-90
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
  • Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients.
  • The study included 72 patients with NHL (42 follicular and 30 large cells).
  • Sixty-four patients (88.9%) had stage III-IV disease.
  • Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m(2)) in 34 (47.2%) and the results of 132 procedures were analyzed.
  • At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy).
  • Pre-apheresis CD34+ blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34+ cells in the apheresis product.
  • The mobilizing regimens (CPM or DHAP) were similar in achieving the threshold CD34+ cell yield, for optimal engraftment.
  • Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Cisplatin. Cyclophosphamide / administration & dosage. Cytarabine. Dexamethasone. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Hematopoietic Stem Cell Transplantation. Humans. Leukocyte Count. Male. Middle Aged. Prospective Studies. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11896424.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


Advertisement
4. Choo SP, Lim ST, Wong EH, Tao M: Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy. Onkologie; 2006 Feb;29(1-2):14-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy.
  • PURPOSE: This paper is to determine the clinicopathological features and outcome of patients with breast lymphoma seen at a single institution.
  • PATIENTS AND METHODS: We have reviewed data on 14 patients with breast lymphoma seen at our institution from 1990 to 2003.
  • Diffuse large B-cell lymphoma (DLBCL) was observed in 9 cases, while follicular, Burkitt's, small lymphocytic, MALT and T-cell lymphoma were observed in 1 case each.
  • 5 patients (35.7%) had stage IE disease, 6 patients (42.9%) had stage IIE disease and 3 patients (21.4%) had stage IV disease.
  • Standard CHOP with or without rituximab was given to all patients with aggressive breast lymphoma (n = 10), while 1 patient with Burkitt's lymphoma received a CHOP-based regimen.
  • The 3-year actuarial survival estimate among all 11 patients with aggressive breast lymphoma was 73%.
  • CONCLUSION: Our results indicate that breast lymphoma is not associated with an inferior outcome when treated with standard CHOP-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Lymphoma / drug therapy. Lymphoma / mortality
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Singapore / epidemiology. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514249.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The radiation dose was 39.9-40.5 Gy in 30 fractions.
  • The median treatment time was 22 days with twice-daily involved-field RT.
  • The initial diagnosis was Stage I-II in 56% and Stage III-IV in 44%.
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • The initial treatment was chemotherapy in 32 patients (94%); 71% were refractory to initial chemotherapy and 29% developed a relapse after an initial response.
  • Grade 1 dermatitis was the most common side effect.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Imataki O, Tamai Y, Kawakami K: [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1629-32
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
  • Standard salvage chemotherapy for refractory or relapsed malignant lymphoma has not been defined.
  • The efficacy and feasibility of the ACES regimen, consisting of carboplatin at 100 mg/m(2) on day 1 to 4, etoposide at 80 mg/m(2) on day 1 to 4, high-dose Ara-C at 2 g/m(2) on day 5 and methylprednisolone at 500 mg/day for 5 days, for refractory or relapsed lymphoma were retrospectively reviewed in comparison with the ESHAP regimen.
  • The subjects were 29 patients, including 7 aggressive follicular lymphomas, 16 large B cell lymphomas and 6 Hodgkin lymphomas.
  • Characteristics of patients with ESHAP (19 cases) and the ACES (10 cases) group were as follows: male/female ratio, 10/9 and 3/7; median age, 49 (range, 31-72) and 54 (22-65); and initial clinical stage (I and II / III / IV), 5/8/6 and 1/1/8, respectively.
  • We concluded that the ACES regimen had a possibility of effective consolidation therapy for the elderly aiming to undergo autologous stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / therapeutic use. Cisplatin / toxicity. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Cytarabine / toxicity. Etoposide / administration & dosage. Etoposide / therapeutic use. Etoposide / toxicity. Female. Humans. Male. Methylprednisolone / administration & dosage. Methylprednisolone / therapeutic use. Methylprednisolone / toxicity. Middle Aged. Retrospective Studies. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940378.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


7. Liu MT, Hsieh CY, Wang AY, Pi CP, Chang TH, Huang CC, Huang CY: Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases. Ann Saudi Med; 2005 Jul-Aug;25(4):288-93
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases.
  • BACKGROUND: Primary breast lymphoma is a rare disease.
  • The small number of patients and the paucity of data make large-series studies difficult.
  • We conducted a pooled analysis to evaluate the treatment outcome and prognostic factors in patients with primary breast lymphoma.
  • Treatments included single therapy or combined surgery, chemotherapy and radiotherapy.
  • We analyzed the correlation between treatment protocols, tumor relapse and survival.
  • Histopathology and cancer stage were analyzed to evaluate their significance in treatment outcome.
  • The histopathology of 63 patients (68%) was diffuse large cell lymphoma.
  • According to Ann Arbor classification, 57% were stage I, 23% were stage II, 4% were stage III, and 16% were stage IV.
  • Thirteen percent received surgery alone, 27% received chemotherapy alone, 7% received radiotherapy alone, 10% received surgery and chemotherapy, 10% received surgery and radiotherapy, 22% received chemotherapy and radiotherapy, and 11% received surgery combined with chemotherapy and radiotherapy.
  • The mean time to first tumor relapse after treatment was 20 months.
  • Tumor stage was a significant prognostic factor affecting overall survival, disease-free survival and disease-specific survival (P=0.0231, 0.0015, 0.0124, respectively).
  • Patients who received chemotherapy and radiotherapy had better survival outcome and a lower relapse rate.
  • We suggestthat chemotherapy and radiotherapy be the initial treatment for patients with primary breast lymphoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / therapy. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / epidemiology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16212120.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


8. Allam W, Ismaili N, Elmajjaoui S, Elgueddari BK, Ismaili M, Errihani H: Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients. BMC Ear Nose Throat Disord; 2009;9:11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively reviewed the records of 26 patients having primary NNHL who were managed between January 1997 and December 2008, to evaluate and compare their clinical characteristics and treatment outcome.
  • Clinical variables, including age, sex, stage, and treatment modality, were assessed.
  • Histology of NNHL were mainly large B-cell and follicular lymphoma.
  • Four patients (15.4%) were at stage I, 15 (57.6%) at stage II, and 7 (27%) were at stage III/IV.
  • The patients were treated with chemotherapy alone (27%) or chemotherapy plus radiotherapy (73%).
  • At early stage (stage I/II), the patients were managed with chemo-radiotherapy.
  • When the whole treatment was completed, 18 patients (69.2%) achieved complete response and remained disease free.
  • The difference in term of overall and disease free survival between stage I, II, III and IV was significant (Log rank test: p = 0.02 for overall survival and p = 0.01 for disease free survival).
  • CONCLUSION: From our study, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are particular and more studies have to be directed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1992;49(6):484-8 [1465289.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):391-5 [16053848.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):194-201 [17604660.001]
  • [Cites] Cases J. 2008;1(1):426 [19116013.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1984;101(8):621-5 [6534256.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Aug;56(2):151-6 [6578477.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):653-61 [6766790.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1995 Apr;20(2):139-44 [7634520.001]
  • [Cites] Curr Top Pathol. 1996;90:125-46 [8791750.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(6):379-87 [10663327.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov;92(5):519-25 [11709688.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Radiol Clin North Am. 1990 Jul;28(4):723-43 [2190267.001]
  • (PMID = 19919708.001).
  • [ISSN] 1472-6815
  • [Journal-full-title] BMC ear, nose, and throat disorders
  • [ISO-abbreviation] BMC Ear Nose Throat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2780375
  •  go-up   go-down


9. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F: Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol; 2000 Dec;11(12):1551-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.
  • PURPOSE: Investigators disagree on whether follicular large cell lymphoma (FLCL) behaves like other follicular lymphomas, with no plateau in the survival curve, or as a more aggressive but potentially curable lymphoma.
  • PATIENTS AND METHODS: Sixty-two patients referred from 1973-1981, including fifteen (24%) patients with Ann Arbor stage I-II and forty-seven (76%) with stage III-IV FLCL.
  • Seven patients received radiation (XRT) alone, forty patients XRT and chemotherapy, and fifteen patients received chemotherapy alone.
  • Univariate analysis revealed that age, Ann Arbor stage, and the International Index correlated with survival.
  • CONCLUSIONS: FLCL responds to doxorubicin-based regimens similarly to diffuse large cell lymphoma.
  • Variables that predict the survival in aggressive lymphomas apply as well in this type of lymphoma.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205462.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


10. Avilés A, Neri N, Cuadra I, Alvarado I, Fernández R, Calva A, Huerta-Guzmán J: Lack of prognostic factors in follicular lymphoma. Leuk Lymphoma; 2003 Jan;44(1):143-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of prognostic factors in follicular lymphoma.
  • We performed a retrospective analysis of prognostic factors in patients with stage III and IV and high-tumor burden follicular lymphoma (FL) treated with uniform schedules and with a long term follow-up.
  • Eight-hundred and ten patients treated with intensive, anthracycline-based, chemotherapy and adjuvant radiotherapy to sites of initial bulky nodal disease were the basis of this analysis.
  • We developed a score system and only two groups (score 0 and 1 and score 2 and 3) showed statistical significance in OS.
  • In conclusion, it is mandatory for multicentric international clinical analysis to define prognostic factors and search for a clinical classification, as in diffuse large B cell lymphoma, so as to define groups of FL for more aggressive or conservative therapy.
  • [MeSH-major] Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment. Severity of Illness Index. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691155.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Grupka NL, Seinfeld J, Ryder J, Lillehei KO, Kleinschmidt-Demasters BK: Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature. Surg Neurol; 2006 Jun;65(6):590-4
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature.
  • BACKGROUND: We report a patient with indolent stage IV follicular lymphoma, grade 1, initially successfully treated with chemotherapy, who later developed aggressive diffuse large B-cell lymphoma in the parieto-occipital lobe 8 years after initial presentation.
  • The differing patterns of lymphomatous involvement of the central nervous system (CNS) are briefly reviewed, with a focus on the patterns seen in secondary CNS spread by low-grade lymphomas.
  • CASE DESCRIPTION: A 53-year-old man was diagnosed with stage IV follicular lymphoma, grade 1, in 1996.
  • Although initial chemotherapy was successful, he developed several recurrences of lymphoma over the following years.
  • The mass proved to be an aggressive diffuse large B-cell lymphoma, transformed from his previous follicular cell lymphoma, with retention of strong Bcl-2 and Bcl-6 immunoreactivity.
  • More significantly, follicular lymphomas are one of the least frequent types of indolent lymphomas to develop clinically apparent, secondary CNS spread.
  • The presentation of an indolent follicular lymphoma with transformation to an aggressive diffuse large B-cell lymphoma within the brain parenchyma is rare.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Occipital Lobe / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Antigens, CD / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720183.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 16
  •  go-up   go-down


12. Knight C, Maciver F: The cost-effectiveness of rituximab in non-Hodgkin's lymphoma. Expert Rev Pharmacoecon Outcomes Res; 2007 Aug;7(4):319-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cost-effectiveness of rituximab in non-Hodgkin's lymphoma.
  • Rituximab is indicated: as the first-line treatment of diffuse-large B-cell non-Hodgkin's lymphoma (NHL) in combination with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); as the first-line treatment of stage III-IV follicular NHL in combination with cyclophosphamide, vincristine and prednisolone (CVP); for the treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or in their second or subsequent relapse after chemotherapy; and as maintenance therapy for patients with relapsed/refractory follicular lymphoma responding to induction therapy with chemotherapy with or without rituximab.
  • This article reviews the published economic evaluations of rituximab in the treatment of NHL.
  • The conclusion of these analyses is that rituximab, used both as monotherapy and in combination with chemotherapy, is a cost-effective intervention in the most common forms of NHL, diffuse large B-cell lymphoma and follicular NHL.
  • If it has the same clinical success in these trials as it has had in diffuse large B-cell lymphoma and follicular lymphoma, then it is possible that within a few years rituximab could play a key role in treating patients in all forms of NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528413.001).
  • [ISSN] 1744-8379
  • [Journal-full-title] Expert review of pharmacoeconomics & outcomes research
  • [ISO-abbreviation] Expert Rev Pharmacoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • Most patients received chemotherapy with or without radiotherapy.
  • The 5-year overall survival for all patients was 56.3% with B and T or NK/T cell lymphomas at 66.0% and 40.6%, respectively.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


14. Crysandt M, Neumann B, Das M, Engelbertz V, Bendel M, Galm O, Osieka R, Jost E: Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol; 2007 Dec;79(6):546-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
  • In the past decade, rituximab in combination with polychemotherapy has become the standard approach in most patients with advanced CD20-positive B-cell lymphoma.
  • In mantle cell lymphoma (MCL), follicular lymphoma and diffuse large B-cell lymphoma, rituximab has been used as monotherapy and in combination with various chemotherapy regimens in different treatment situations.
  • Here, we report a 64-yr-old woman who was previously treated with three different chemotherapy regimens for stage IV MCL.
  • The patient's general status declined and she developed massive ascites as the dominant clinical problem.
  • Local, intraperitoneal administration of rituximab was initiated as an experimental treatment approach.
  • After 11 doses of rituximab, the general status of the patient improved significantly, ascites resolved completely and computed tomography (CT) scans demonstrated a partial remission of intra-abdominal lymph nodes and splenomegaly.
  • The response to the experimental treatment has maintained for more than 6 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Ascites / drug therapy. Infusions, Parenteral / methods. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Anemia / drug therapy. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Rituximab. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903214.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • Four (15.4%) of the patients were at stage I, 15 (57.6%) were at stage II, and 7 (27%) were at stage III/IV.
  • At early stage, the patients were managed with chemo-radiotherapy and were managed with CHOP based chemotherapy at advanced stage.
  • At the end of total treatment, 18 patients (69.2%) achieved complete response and remained disease free while 4 (15.4%) achieved partial response (>70%) and 4 (15.4%) were progressive (these patients received second line chemotherapy).
  • Overall, the treatment was well tolerated.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Weng WK, Czerwinski D, Levy R: FcγR IIIa polymorphism and anti-idiotype humoral immune response predict clinical outcome in follicular lymphoma patients receiving idiotypic vaccination. J Clin Oncol; 2004 Jul 15;22(14_suppl):6503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FcγR IIIa polymorphism and anti-idiotype humoral immune response predict clinical outcome in follicular lymphoma patients receiving idiotypic vaccination.
  • : 6503 Background: The Ig idiotype (Id) expressed by B cell lymphoma is a target for immunotherapy.
  • METHODS: We analyzed 155 follicular lymphoma patients who had Id Vac between 1988 and 2001 at Stanford Medical Center.
  • All patients received induction chemotherapy followed by Id Vac.
  • The humoral IR was associated with longer freedom from progression (FFP) after induction chemotherapy/Id Vac (humoral IR, 6.23 yrs vs other, 2.66 yrs, p=0.006).
  • Patients with FcγRIIIa V/V genotype enjoyed longer FFP than those with V/F or F/F (median time to progression: V/V, 8.21 yrs vs V/F, 2.66 yrs, p=0.002; vs F/F, 2.89 yrs, p=0.021).
  • Multi-variant analysis using the Cox Proportional Hazards Model showed that V/V genotype and humoral IR were two independent positive predictors for disease free survival, and stage IV disease was a negative predictor, while FcγRIIa polymorphism, cellular IR, gender, age, B symptoms or time from diagnosis to therapy had no impact.
  • CONCLUSIONS: There was clinical benefit of humoral anti-Id IR in a large group of patients vaccinated with Id.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Tulpule A, Khan AU, Mohrbacher AF, Espina BM, Buchanan L, Berman N, Gorospe G, Boswell WD, Nathwani BN, Levine AM: A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6688

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
  • METHODS: Patients (pts) received Doxil, 40 mg/m<sup>2</sup>, cyclophosphamide, 750 mg/m<sup>2</sup>, vincristine, 2.0 mg, all given IV on day 1; prednisone, 100 mg was given orally on days 1-5.
  • Rituxan, 375 mg/m<sup>2</sup> IV day 1 was added to the regimen starting cycle 2.
  • Chemotherapy cycles were repeated every 21 days and given until 2 cycles beyond complete remission for a maximum of 8 cycles.
  • Baseline demographics: median age 51 years (range 20-74); all pts were CD20+ positive with diffuse large cell lymphoma in 16, high grade not otherwise specified in 2, and follicular grade 3 in 1.
  • 16 (84%) pts had stage IV disease.
  • In total, 15 pts are evaluable for response: 12 complete or clinical complete remissions (80%) have been documented; 3 pts had partial remission with one proceeding to stem cell transplant.
  • Toxicities have been primarily hematologic with transient grade 3 or 4 neutropenia in 13 (68%) pts.
  • Grade 3 anemia and thrombocytopenia were reported in 1 patient each.
  • Delays in therapy or Doxil dose reductions were required in 5 pts (26%) for grade 2 or 3 hand-foot syndrome (HFS) and in 4 others (21%) for grade 2 mucositis.
  • Other non-hematologic toxicities were grade 1 or 2 in severity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Coffey J, Hodgson DC, Gospodarowicz MK: Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging; 2003 Jun;30 Suppl 1:S28-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of non-Hodgkin's lymphoma.
  • The WHO classification of hematopoietic and lymphoid tumours classifies lymphomas into B-cell and T-cell neoplasms.
  • B-cell lymphomas account for more than 85% of all lymphomas.
  • The two most common histologic disease entities are follicular lymphomas and diffuse large B-cell lymphomas.
  • The management of follicular lymphomas is used as a paradigm for the management of all indolent lymphomas.
  • Radiation therapy is used for stage I and II disease, while alkylating agent chemotherapy, immunotherapy and radioimmunotherapy are most frequently used in stage III and IV disease that requires treatment.
  • Most patients with follicular lymphoma enjoy prolonged survival, but at present there is no evidence that those with stage III and IV follicular lymphoma can be cured.
  • Diffuse large B-cell lymphomas serve as a paradigm for treating aggressive lymphomas.
  • Stage I and II diffuse large cell lymphomas are generally treated with combined modality therapy with doxorubicin-based chemotherapy followed by involved field radiation therapy, while those with stage III and IV disease are treated with chemotherapy alone.
  • Patients who fail initial management are treated with further chemotherapy.
  • High-dose chemotherapy with stem cell rescue has been shown to be particularly effective as salvage treatment for diffuse large cell lymphomas.
  • The management of a heterogeneous group of primary extranodal lymphomas in general follows the above treatment principles, with additional treatment being required for those with a high risk of CNS failures, or involvement of contralateral paired organs.
  • The management of MALT lymphomas, especially gastric MALT lymphoma, deserves special attention because of the high response rate to Helicobacter pylori eradication therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Combined Modality Therapy. Female. Humans. Immunotherapy. Male. Neoplasm Staging. Peripheral Blood Stem Cell Transplantation. Radioimmunotherapy. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1341-6 [12196358.001]
  • [Cites] Important Adv Oncol. 1994;:117-29 [8206485.001]
  • [Cites] N Engl J Med. 1993 Nov 25;329(22):1608-14 [8232429.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):29-35 [11437398.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4022-31 [12351600.001]
  • [Cites] J Clin Oncol. 2000 May;18(10 ):2010-6 [10811664.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):792-7 [8471438.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leuk Lymphoma. 1992 May;7(1-2):135-8 [1472924.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3545-57 [12177115.001]
  • [Cites] Lancet. 1993 Dec 18-25;342(8886-8887):1514-6 [7902900.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1337-49 [12128137.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1347-55 [12196359.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1659-67 [11527693.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):643-51 [11849785.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B66-72 [11757712.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):280-2 [11807154.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9 [11395243.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3800-7 [8204898.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • (PMID = 12692688.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 54
  •  go-up   go-down


19. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM: Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol; 2005 Oct;131(2):193-200
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.
  • Central nervous system (CNS) involvement in non-Hodgkin lymphoma (NHL) is a well-recognised complication.
  • A total of 223 questionnaires were sent to clinicians who administered chemotherapy to patients with NHL; 158 (71%) evaluable questionnaires were returned.
  • The overwhelming majority of respondents used prophylaxis in all cases of lymphoblastic lymphoma (97%) and Burkitt lymphoma (96%).
  • Ninety-six per cent of respondents required risk factors to be present before prophylaxis was initiated in cases of diffuse large B-cell lymphoma.
  • Other risk factors included stage IV, high International Prognostic Index score, >1 extranodal site and raised lactate dehydrogenase levels (34%, 21%, 16% and 10%).
  • A total of 82% did not give prophylaxis in follicular lymphoma and 90% used intrathecal chemotherapy as their preferred method of prophylaxis.
  • The most popular regimen was 12.5 mg methotrexate with each cycle of chemotherapy for six courses.
  • Thirty-nine per cent used systemic chemotherapy for CNS prophylaxis either alone (4%) or as an adjunct to intrathecal prophylaxis (35%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Lymphoma, Non-Hodgkin / drug therapy. Patient Selection. Practice Patterns, Physicians'
  • [MeSH-minor] Antibiotic Prophylaxis. Burkitt Lymphoma / drug therapy. Chemoprevention. Great Britain. Humans. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Dec;131(5):673
  • (PMID = 16197449.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Marcus R, Hagenbeek A: The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl; 2007 Jan;(67):5-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic use of rituximab in non-Hodgkin's lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for approximately 30% of all new patients.
  • Follicular lymphoma (FL) is the second most common NHL sub-type, and accounts for a further 22% of cases.
  • Over the last five years, the introduction of monoclonal antibodies, and specifically the anti-CD20 monoclonal antibody, rituximab, has radically changed treatment of B-cell NHL.
  • This antigen is expressed on over 95% of all B cell NHLs, and on normal B cells, but not on haematopoietic stem cells, normal or malignant plasma cells.
  • The Fc domain of rituximab recruits immune effector functions to mediate B cell lysis.
  • It is also possible that the binding of rituximab to the CD20 antigen on the cell surface may directly induce apoptosis.
  • For patients with both follicular and diffuse large B-cell NHL, several large scale prospective randomised trials have demonstrated prolongation of remission when rituximab is incorporated into first line treatment, and, in follicular lymphoma, as a component of salvage therapy.
  • As a result of these studies, current European indications for rituximab include: the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with cyclophosphamide, vincristine and prednisone (CVP) chemotherapy; as maintenance therapy in patients with relapsed follicular lymphoma responding to induction therapy with chemotherapy or immuno-chemotherapy; the treatment of patients with diffuse large B cell NHL in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Kaplan-Meier Estimate. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Recurrence. Rituximab. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206982.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 39
  •  go-up   go-down


21. Ansell SM, Armitage J: Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc; 2005 Aug;80(8):1087-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma: diagnosis and treatment.
  • Based on the World Health Organization classification of hematological and lymphoid tumors, these diseases have been classified as B-cell and T-cell neoplasms.
  • B-cell lymphomas account for approximately 90% of all lymphomas, and the 2 most common histological disease entities are follicular lymphoma and diffuse large B-cell lymphoma.
  • Approximately 55,000 to 60,000 new cases of non-Hodgkin lymphoma are diagnosed annually in the United States, a number that has nearly doubled during the past 3 decades.
  • Also, recent data have identified molecular and genetic markers of prognosis that may be used in the future to further refine treatment decisions.
  • Treatment of these diseases is based on the histology and extent of disease.
  • Patients with follicular lymphomas with early-stage disease generally are treated with radiation therapy, whereas those with stage III and IV disease requiring treatment usually are treated with chemotherapy, Immunotherapy, or radioimmunotherapy.
  • For patients with diffuse large B-cell lymphoma, treatment of limited-stage disease generally includes doxorubicin-based chemotherapy combined with rituximab followed by involved field radiation therapy.
  • Those with extensive disease are treated with rituximab combined with chemotherapy alone.
  • Disease relapse is a problem, and high-dose therapy with stem cell support is the treatment of choice for chemosensitive relapsed aggressive lymphomas.
  • Patients with chemoresistant disease or whose disease relapses subsequently should be treated with novel experimental therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. L-Lactate Dehydrogenase / blood. Middle Aged. Phenotype. Prognosis. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092591.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 74
  •  go-up   go-down


22. Suzumiya J, Suzushima H, Maeda K, Okamura S, Utsunomiya A, Shibuya T, Tamura K, Kyushu Hematology Organization for Treatment Study Group: Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol; 2004 Apr;79(3):266-70
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.
  • A phase I study of irinotecan hydrochloride (CPT-11), carboplatin, and dexamethasone treatment in 7 patients with relapsed lymphoma and 7 patients with refractory lymphoma was conducted to evaluate the maximal tolerated dose.
  • The 6 female and 8 male patients had a median age of 63 years (range, 45-73 years), a median performance status of 0 (range, 0-2), and a median disease stage of IV.
  • This study included patients with diffuse large B-cell lymphoma (n = 5), adult T-cell leukemia/lymphoma (n = 2), mantle cell lymphoma (n = 2), follicular lymphoma (n = 2), angioimmunoblastic T-cell lymphoma (n = 1), anaplastic large cell lymphoma (n = 1), and Hodgkin's lymphoma (n = 1).
  • All patients had received anthracycline-containing combination chemotherapy prior to this therapy.
  • Ten patients (71%) and 11 patients (79%) experienced grade 3 or 4 hematologic toxicities of leukocytopenia and neutropenia, respectively.
  • Three patients (29%) and 9 patients (64%) experienced grade 3 or 4 thrombocytopenia and anemia, respectively.
  • Two patients who received 30 mg/m2 (level 4) of CPT-11 developed sepsis.
  • No deaths were related to this chemotherapy, and no patient developed liver dysfunction.
  • We conclude that the combination therapy of CPT-11, carboplatin, and dexamthasone is effective as salvage therapy but that the duration of response is too short.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / analogs & derivatives. Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1994 Oct;70(4):771-4 [7917938.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):594-600 [11857289.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Jul;15(7):2145-51 [3293537.001]
  • [Cites] Jpn J Clin Oncol. 1996 Dec;26(6):455-60 [9001351.001]
  • [Cites] Semin Oncol. 1996 Feb;23 (1 Suppl 3):21-6 [8633249.001]
  • [Cites] Gan To Kagaku Ryoho. 1991 Aug;18(10 ):1681-9 [1872624.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):115-6 [10690400.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1907-12 [2230878.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):604-10 [1537625.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):411-6 [11529467.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Rinsho Ketsueki. 1994 Jul;35(7):635-41 [8065017.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):71-4 [3342468.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4187-91 [1651156.001]
  • [Cites] J Clin Oncol. 1992 Jan;10 (1):16-20 [1309380.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):909-13 [8487053.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1047-55 [8210256.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3633-42 [11054436.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):577-86 [11697485.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Aug;21(10 ):1607-11 [8060135.001]
  • (PMID = 15168596.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Wood L, Robinson R, Gavine L, Juritz J, Jacobs P: A single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci; 2007 Aug;37(1):93-102
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single unit lymphoma experience: outcome in a Cape Town academic centre.
  • Diagnosis was according to World Health Organization criteria, prognosis assigned by the international index and therapy risk-stratified with results subject to appropriate statistical methodology.
  • Constitutional symptoms were present in 22%; a quarter had previous chemotherapy and a third some form of irradiation prior to referral.
  • Fifty-seven percent were stage I or II and 21% had nodal disease above and below the diaphragm whilst in the remainder cells were present in the circulation and this included the subset of chronic lymphocytic leukaemia -- small lymphocytic lymphoma.
  • Further adverse factors included any prior treatment, intermediate or high-grade histopathology, risk factors defined by the International Prognostic Index as well as late Rai stages.
  • Analysed by disease category Hodgkin lymphoma (n=17) when managed according to the German Study Group protocols and hairy cell leukaemia (n=10) treated with two chlorodeoxyadenosine -- both had a stable plateau in excess of 90%.
  • The corresponding figures for follicular variants (n=31) was 72% in the low risk and 58% in the remainder when treated with cyclophosphamide, vincristine and prednisone.
  • Curves for the aggressive or diffuse large B-cell lymphoma (n=44) fell initially to 48%, but relapse continued in stages III and IV to the current level of 18% when receiving cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone on the 21-day schedule.
  • Chronic lymphocytic leukaemia -- small lymphocytic lymphoma (n=58) were initially given pulsed chlorambucil and sustained response was over 90% with low bulk, but declined to reach 30% as prognostic score rose.
  • It is concluded that precise diagnosis, accurate staging and therapy on standardised risk-stratified programmes, delivered uniformly by a single multidisciplinary group, creates the all-important centre effect; matching figures are unlikely to apply outside these disciplined circumstances.
  • It follows that late referral and prior therapy will adversely affect performance status and compromise life span: These alternative approaches are inappropriate and strongly discouraged.
  • [MeSH-major] Hospitals, Private. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Cohort Studies. Developing Countries. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. South Africa. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931976.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kuo MC, Tang CC: Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan. Acta Haematol; 2004;112(4):203-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan.
  • Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001.
  • The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient.
  • Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma.
  • Six patients were in stage I, 4 in II, 1 in III and 12 in IV.
  • Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma.
  • Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome.
  • All the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment.
  • Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients.
  • However, a high relapse rate (9/16, 56%) was noted in stage II-IV patients.
  • These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy.
  • One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease.
  • Thus, salivary gland lymphoma proved to be an indolent disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Autoimmune Diseases / complications. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / complications. Male. Middle Aged. Radiotherapy. Remission Induction. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564732.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Winnicki M, Gariepy G, Sauthier PG, Funaro D: Hodgkin lymphoma presenting as a vulvar mass in a patient with crohn disease: a case report and literature review. J Low Genit Tract Dis; 2009 Apr;13(2):110-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma presenting as a vulvar mass in a patient with crohn disease: a case report and literature review.
  • OBJECTIVE: A case of Hodgkin lymphoma of the vulva and perineum is presented along with a review of the literature.
  • RESULTS: A 45-year-old female patient with a longstanding history of Crohn disease presented with a large vulvar and perineal mass.
  • Incisional biopsy of the vulvar mass revealed histologic diagnosis and immunohistochemistry typical of classic Hodgkin lymphoma.
  • The patient was designated as having stage IV disseminated Hodgkin lymphoma, and chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted.
  • A significant reduction of the size of the vulvar mass was observed following 8 cycles of chemotherapy.
  • CONCLUSIONS.: Lymphoma of the vulva is rare with the majority being of the non-Hodgkin lymphoma type.
  • The most common subtypes of vulvar lymphoma reported are diffuse large B-cell lymphoma and follicular lymphoma.
  • Perianal Hodgkin lymphoma is also very rare but has been reported in association with human immunodeficiency virus infection, Epstein-Barr virus infection, and Crohn disease.
  • This is only the second reported case of Hodgkin lymphoma of the vulva and the second case of Hodgkin lymphoma involving the perianal area in a female patient.
  • There is currently no evidence that Crohn disease is associated with an increased risk of Hodgkin lymphoma.


26. Moreno M, Sancho JM, Gardella S, Coll R, García O, Gallardo D, Ribera JM: [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients]. Med Clin (Barc); 2010 Jan 30;134(2):72-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
  • [Transliterated title] Doxorrubicina liposomal no pegilada en combinación con ciclofosfamida, vincristina, prednisona y rituximab en el tratamiento de linfomas no hodgkinianos: estudio de 26 pacientes.
  • BACKGROUND AND OBJECTIVES: Non-pegylated liposomal doxorubicin is associated with lower cardiac toxicity than conventional doxorubicin, and for that reason it has been used in the treatment of non-Hodgkin's lymphoma (NHL) in old patients or patients with cardiac disease.
  • The objective of this study was to evaluate the efficacy and safety of chemotherapy schedules including non-pegylated liposomal doxorubicin in patients with NHL.
  • In each patient demographic data, clinical and biological variables, as well as therapy, response and toxicity were recorded.
  • The most frequent histological diagnosis was diffuse large B cell lymphoma (DLBCL, 20 patients).
  • The stage disease at diagnosis was III/IV in 19 (73%) patients whereas 12 (57%) of the 21 patients with DLBCL and grade 3 follicular lymphoma had a high-risk International Prognostic Index.
  • Three patients had a left ventricular ejection fraction lower than 50% at the time of starting treatment.
  • In all cases non-pegylated liposomal doxorubicin was administered as part of the R-COMP schedule (rituximab, cyclophosphamide, vincristin, non-pegylated liposomal doxorubicin and prednisone), in 20 cases (73%) as first-line treatment and in the remaining 6 as salvage therapy.
  • Two patients died after the first cycle of chemotherapy (one because of sudden death and the other due to disease progression).
  • Eleven (61%) out of the 18 patients receiving R-COMP as first-line therapy achieved a complete response (CR), 5 (28%) achieved partial response (PR) and 2 showed progression.
  • Only one out of the 6 patients receiving R-COMP as salvage therapy achieved CR, whereas 3 had PR and 2 did not respond.
  • Grade 3 or 4 neutropenia was observed in 11 (46%) patients and febrile neutropenia in 10 (42%), while only one patient developed grade 4 thrombocytopenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19913261.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Liposomes; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


27. Diop S, Deme A, Dangou JM, Ndiaye FS, Toure AO, Thiam D, Diop TM, Toure P, Diakhate L: [Non-Hodgkin's lymphoma in Dakar: study of 107 cases diagnosed between 1986 and 1998]. Bull Soc Pathol Exot; 2004 May;97(2):109-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphoma in Dakar: study of 107 cases diagnosed between 1986 and 1998].
  • At moment of diagnosis, 72% of patients were in stage III or IV according to the Ann Arbor Staging System.
  • Large cell lymphomas were predominant (67.2%), followed by small lymphocyte lymphomas (24.2%) and follicular lymphoma with 8.4% of cases.
  • Chemotherapy was used in 54 patients (78.2% of treated patients), surgery was performed in 6 patients (8.6%), association of radiotherapy and chemotherapy in 5 patients (7.2%) and 4 patients (5.7%) were treated with surgery + chemotherapy.
  • The average survival time was 344 days.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Urban Health / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. HIV Infections / complications. HIV Infections / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Population Surveillance. Prevalence. Prognosis. Risk Factors. Senegal / epidemiology. Sex Distribution. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15255352.001).
  • [ISSN] 0037-9085
  • [Journal-full-title] Bulletin de la Société de pathologie exotique (1990)
  • [ISO-abbreviation] Bull Soc Pathol Exot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.
  • RESULTS: Veltuzumab was well tolerated, with no grade 3 to 4 drug-related adverse events despite short infusion times (typically 2 hours initially, 1 hour subsequently at doses < 375 mg/m(2)).
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • At all dose levels studied, B cells were depleted after the first infusion, veltuzumab serum half-lives were similar after the fourth infusion, and mean antibody serum levels exceeded values considered important for anti-CD20 therapy (ie, 25 microg/mL).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


29. Shimazaki K, Ohshima K, Haraoka S, Suzumiya J, Nakamura N, Kikuchi M: Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells. Histopathology; 2002 Jan;40(1):12-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells.
  • AIMS: Lymph nodes contain non-lymphoid accessory cells including follicular dendritic cells and interdigitating dendritic cells.
  • We present here the clinicopathological features of 16 cases of accessory cell tumour.
  • Electron microscopic examination showed that many of the tumour cells had numerous interwoven long villous cell processes connected by occasional desmosomes.
  • Many tumours were very refractory to chemotherapy and radiation, with a few exceptions, and half of the cases classified initially as stage IV.
  • A short survival time, of 10 months or less, was observed in seven of 16 patients.
  • CONCLUSIONS: Our study identified more aggressive behaviour of accessory cell tumours.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Herpesvirus 4, Human / isolation & purification. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Reed-Sternberg Cells / pathology. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11903594.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


30. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M: CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol; 2000 Jan;16(1):149-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
  • From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM.
  • Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV.
  • At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM].
  • Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046).
  • Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups.
  • It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively).
  • Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively.
  • In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601560.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CEOP-B protocol; PROMACE-CytaBOM protocol
  •  go-up   go-down


31. Medvedev PV, Nikitin EA, Pivnik AV: [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients]. Ter Arkh; 2000;72(7):38-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
  • AIM: To evaluate toxicity and efficacy of CDxOP regimen in the treatment of primary non-Hodgkin's lymphoma (PNHL).
  • MATERIAL AND METHODS: The study included 8 males and 6 females who had large B-cell lymphoma (n = 11), follicular lymphoma, predominantly large cell (n = 1), mantle cell lymphoma (n = 1) and peripheral T-cell lymphoma (n = 1).
  • PNHL stage IV, III and II was diagnosed in 7, 5 and 2 patients, respectively.
  • The other drugs were used in standard doses.
  • Three patients did not respond to therapy and died.
  • The results of the treatment are comparable with those of standard chemotherapy.
  • Further comparative studies are needed for determination of efficacy and maximal tolerated dose of daunoxome in combination with other drugs and irradiation, of long-term side effects.
  • This drug may be beneficial for elderly patients.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Daunorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Heart / drug effects. Humans. Liposomes. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983319.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


32. Oriuchi N, Higuchi T, Endo K, Tsukamoto N, Matsuda H, Kuji I, Murakami K, Nakajima K: [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients]. Kaku Igaku; 2009 Jun;46(2):96-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
  • Positron emission tomography (PET) with [18F] fluoro-2-deoxy-D-glucose (FDG) is used for the diagnosis of various types of cancer.
  • FDG-PET is used also for the assessment of therapeutic response as well as work-up of recurrence after therapy.
  • Due to the characteristics of FDG-PET as an imaging tool, FDG-PET is supposed to be superior to the conventional imaging such as CT for the accurate assessment of the treatment response in patients with malignant lymphoma.
  • Malignant lymphoma usually undergoes chemotherapy or chemoimmunotherapy as a treatment of stage III and IV patients.
  • Recent advancement in the therapy of malignant lymphoma enables optional treatment strategies such as radioimmunotherapy with 90Y-labeled anti-CD20 monoclonal antibody or oral fludalabine for indolent non-Hodgkin's lymphoma and high-dose chemotherapy with autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.
  • The purpose of the present study was to determine the clinical value of FDG-PET for the early assessment of therapeutic response of malignant lymphoma.
  • Twenty-six patients with malignant lymphoma were enrolled in the study.
  • The subject consists of 10 patients with follicular lymphoma, 9 diffuse large B-cell lymphoma, and others.
  • Therapeutic regimens were rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 19 patients, CHOP and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 2 patients each, and others.
  • FDG-PET was performed before the initiation of therapy in all patients and after the therapy of 1-2 courses in 5 patients; and 3-4 courses, 5-6 courses, and 7-8 courses in 7 patients each.
  • In patients who underwent multiple PET studies during the treatment, all 4 patients showed CR(PET) in its first assessment, and maintained CR thereafter.
  • The present study revealed that most of the patients achieved CR(PET) up to 4 courses of therapy.
  • The cases with remaining FDG uptake at this time were likely to be resistant to the therapy.
  • The early assessment of therapeutic response may be accurately assessed by FDG-PET as early as 2 or 4 courses of therapy.
  • Residual uptake of FDG in the lesion would be considered to be subject to the new therapeutic strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. Lymphoma / drug therapy. Lymphoma / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637820.001).
  • [ISSN] 0022-7854
  • [Journal-full-title] Kaku igaku. The Japanese journal of nuclear medicine
  • [ISO-abbreviation] Kaku Igaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; CHOP protocol
  •  go-up   go-down






Advertisement